Solution of the Structure of the TNF-TNFR2 Complex

@article{Mukai2010SolutionOT,
  title={Solution of the Structure of the TNF-TNFR2 Complex},
  author={Yohei Mukai and Teruya Nakamura and Mai Yoshikawa and Yasuo Yoshioka and Shin-ichi Tsunoda and Shinsaku Nakagawa and Yuriko Yamagata and Yasuo Tsutsumi},
  journal={Science Signaling},
  year={2010},
  volume={3},
  pages={ra83 - ra83}
}
Structural differences in the binding of tumor necrosis factor to its two receptors may aid in the development of receptor-specific therapeutics. Structural Differences The proinflammatory cytokine tumor necrosis factor (TNF) functions in the immune response; however, TNF also plays a pathophysiological role in diseases such as rheumatoid arthritis and Crohn’s disease. The effects of TNF are mediated by TNF receptor 1 (TNFR1) and TNFR2; whereas TNFR1 is ubiquitously expressed, TNFR2 is mostly… 
Structural basis for signal initiation by TNF and TNFR
TLDR
It was observed that the TNF–TNFR2 complexes form aggregates on the cell surface, suggesting two-dimensional network models for the signal initiation through TNFR2, and may be useful information for the design of receptor-selective drugs.
Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target
TLDR
With respect to its preference for Treg stimulation and protection of non-immune cells, TNFR2 is more unique and thus offers opportunities for translational success, and this approach is just one amongst many suitable targets.
Structural Basis for Treating Tumor Necrosis Factor α (TNFα)-associated Diseases with the Therapeutic Antibody Infliximab*
TLDR
These results provide the first experimental model for the interaction of TNFα with therapeutic antibodies and offer useful information for antibody optimization by understanding the precise molecular mechanism of T NFα inhibition.
Noncompetitive inhibitors of TNFR1 probe conformational activation states
TLDR
A small molecule that noncompetitively inhibits TNFR1 could be optimized to treat inflammatory diseases and residues in the ligand-binding loop that are critical to the dynamic coupling between the extracellular and the transmembrane domains played a key gatekeeper role in the conformational dynamics associated with signal propagation.
Insights into ligand binding by a viral tumor necrosis factor (TNF) decoy receptor yield a selective soluble human type 2 TNF receptor
TLDR
This work is the most detailed study of the v TNFR–ligand interactions to date and illustrates that a better knowledge of vTNFRs can provide valuable information to improve current anti-TNF therapies.
The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond.
TLDR
There remains a need to better understand the fundamental mechanisms underlying the molecular pathways they mediate to design more effective anti-inflammatory and anti-cancer therapies.
Structural basis for tumor necrosis factor blockade with the therapeutic antibody golimumab
TLDR
Golimumab exerts its inhibitory effect by preventing binding of TNFR1 and TNFR2 to TNFα by steric hindrance, and this mode of action is specific to golimumab among the four anti‐TNFα therapeutic antibodies currently approved for clinical use.
Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
TLDR
The latest works on the structural characterization of TNFα–TNFα antagonist interactions related to their therapeutic efficacy at the atomic level are described and can provide a basis for the improvement of therapeutic agents against TNF α for the treatment of rheumatoid arthritis and other autoimmune inflammatory diseases.
Small-molecule inhibitors of the interaction between TNF and TNFR.
TLDR
The various strategies used in obtaining small-molecule, nonpeptide, inhibitors of the TNF-TNF receptor interaction through disruption of theTNF trimer or direct inhibition of the H2O receptor interaction are presented here.
Development and Characterization of a Potent Tumor Necrosis Factor-Alpha-Blocking Agent.
TLDR
This study characterized several hybridoma clones secreting monoclonal antibodies to human-TNFα and found the binding affinity of mAb C8 to TNFα was found to be comparable with that of infliximab, which is a commercially available anti-T NFα mAb.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 93 REFERENCES
Structure-activity studies of human tumour necrosis factors.
The mechanism by which tumour necrosis factors (TNF and lymphotoxin, also called TNF alpha and TNF beta respectively) exert their cytotoxic activity on many malignant cells, remains largely unknown.
Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors
TLDR
It is found that soluble versions of PLAD, especially those derived from P60, block the biochemical effects of TNF-α in vitro and potently inhibit arthritis in animal models, suggesting that targeting the PLAD may have clinical value in the treatment of human arthritis.
The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis models.
Creation and X-ray Structure Analysis of the Tumor Necrosis Factor Receptor-1-selective Mutant of a Tumor Necrosis Factor-α Antagonist*
TLDR
The studies demonstrate the feasibility of generating TNF receptor subtype-specific antagonist by extensive substitution of amino acids of the wild-type ligand protein by eliminating six amino acid residues at the receptor-binding site.
Crystallographic Evidence for Dimerization of Unliganded Tumor Necrosis Factor Receptor (*)
TLDR
The structure of the type I TNF receptor extracellular domain (sTNF-R1), crystallized in the absence of TNF, has been determined at 2.25-Å resolution and contrary to expectations, the unliganded domains are found to associate into dimers of two distinct types, in which monomers are related by local two-fold axes of symmetry.
Viral TNF inhibitors as potential therapeutics.
TLDR
Biological molecules with a different mode of action in regulating TNF biology might provide a clinically useful alternative to the current therapeutics or in some cases might be efficacious in combination with existinganti-TNF therapies.
...
1
2
3
4
5
...